Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Novel Targeted Therapies for Inflammatory Bowel Disease

Research output: Contribution to journalReviewpeer-review

  1. Identifying New Antimigraine Targets: Lessons from Molecular Biology

    Research output: Contribution to journalReviewpeer-review

  2. High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Heteromeric α7β2 Nicotinic Acetylcholine Receptors in the Brain

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Emerging migraine treatments and drug targets

    Research output: Contribution to journalReviewpeer-review

  5. Interstitial cells of Cajal as targets for pharmacological intervention in gastrointestinal motor disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. A fully defined 3D matrix for ex vivo expansion of human colonic organoids from biopsy tissue

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mucosal vitamin D signaling in inflammatory bowel disease

    Research output: Contribution to journalReviewpeer-review

  3. Telomere dysfunction activates YAP1 to drive tissue inflammation

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Our growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has opened new avenues for developing targeted therapies. These advances in treatment options targeting different mechanisms of action offer new hope for personalized management. In this review we highlight emerging novel and easily administered therapeutics that may be viable candidates for the management of IBD, such as antibodies against interleukin 6 (IL-6) and IL-12/23, small molecules including Janus kinase inhibitors, antisense oligonucleotide against SMAD7 mRNA, and inhibitors of leukocyte trafficking to intestinal sites of inflammation (e.g., sphingosine 1-phosphate receptor modulators). We also provide an update on the current status in clinical development of these new classes of therapeutics.

Original languageEnglish
JournalTrends in Pharmacological Sciences
Volume38
Issue number2
Pages (from-to)127-142
Number of pages16
ISSN0165-6147
DOIs
Publication statusPublished - Feb 2017

    Research areas

  • Animals, Antibodies, Monoclonal, Humanized, Humans, Indans, Inflammatory Bowel Diseases, Interleukin-23, Interleukin-6, Janus Kinase 1, Oligonucleotides, Antisense, Oxadiazoles, Phenylalanine, Precision Medicine, Quinazolinones, Quinolones, Smad7 Protein, Journal Article, Review

ID: 52418614